Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Unknown unknown|
|Therapy||Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin|
|Indication/Tumor Type||colorectal cancer|
|Response Type||not applicable|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin||Clinical Study||Actionable||In a clinical study, colorectal cancer patients demonstrated a greater median PFS when treated with FOLFOX and Avastin (bevacizumab), which was thought to be associated with a decrease in granulocytic myeloid-derived suppressor cells highly expressing PD-L1 (PMID: 27496709).||27496709|